Metronidazole is used for all of the following conditions except:
All of the following are true of pyrazinamide EXCEPT?
Which drugs are safe in pregnancy for a patient with HIV infection?
Which of the following antifungal drugs is NOT used in the treatment of intestinal candidiasis?
Which of the following is used for the prevention of Pneumocystis jiroveci infection in HIV positive patients?
Ethambutol toxicity is most commonly associated with visual disturbances. Which color vision deficiency is characteristic of ethambutol toxicity?
Which anti-tubercular drug is contraindicated during pregnancy?
Which of the following antiviral drugs is used against HCV infection?
Fomivirsen is used in the treatment of which of the following conditions?
Which of the following is intended for use against HCV?
Explanation: **Explanation:** Metronidazole is a nitroimidazole derivative that acts as a potent **anaerobic bactericide and antiprotozoal agent**. Its mechanism of action involves the intracellular reduction of its nitro group by the enzyme **pyruvate:ferredoxin oxidoreductase (PFOR)**, found only in anaerobic organisms. This process generates reactive free radicals that cause DNA strand breakage and cell death. **Why Malaria is the Correct Answer:** * **Malaria (Option D):** Malaria is caused by *Plasmodium* species, which are aerobic/microaerophilic intracellular protozoa. They lack the PFOR enzyme system required to activate Metronidazole. Malaria is treated with drugs like Chloroquine, Artemisinin derivatives, or Quinine. **Why the other options are incorrect:** * **Amoebiasis (Option A):** Metronidazole is the drug of choice (DOC) for invasive intestinal and extra-intestinal (liver abscess) amoebiasis caused by *Entamoeba histolytica*. * **Giardiasis (Option B):** It is a first-line agent for treating diarrhea caused by *Giardia lamblia*. * **Trichomonas vaginitis (Option C):** It is the DOC for *Trichomonas vaginalis* infections. Both partners must be treated to prevent reinfection. **High-Yield Clinical Pearls for NEET-PG:** 1. **Disulfiram-like reaction:** Patients must avoid alcohol while on Metronidazole due to the inhibition of aldehyde dehydrogenase. 2. **Metallic taste:** A common side effect reported by patients. 3. **Other Indications:** It is the DOC for **Pseudomembranous colitis** (caused by *C. difficile*) and is used in triple therapy for ***H. pylori*** and for anaerobic infections (e.g., brain abscess, aspiration pneumonia). 4. **Mnemonic:** Metronidazole covers **GET GAP** (Giardia, Entamoeba, Trichomonas, Gardnerella, Anaerobes, Pylori).
Explanation: **Explanation:** Pyrazinamide (PZA) is a cornerstone of modern antitubercular therapy (ATT), but its safety profile in pregnancy remains a point of distinction in medical guidelines. **Why Option B is the correct answer (The Exception):** According to the **RNTCP (now NTEP) and WHO guidelines**, pyrazinamide is **not contraindicated** in pregnancy. It is routinely used in the standard 6-month "DOTS" regimen for pregnant women. While the US-FDA previously categorized it as Category C due to a lack of extensive teratogenicity data, clinical experience has shown it to be safe. Therefore, stating it is contraindicated is factually incorrect in the context of standard medical practice. **Analysis of Incorrect Options:** * **Option A:** PZA is uniquely effective against **intracellular bacilli** residing within acidic environments (phagosomes of macrophages). It is known as the "sterilizing agent" because it kills slowly multiplying dormant bacilli. * **Option C:** PZA exhibits **excellent CNS penetration**. It crosses the blood-brain barrier effectively, making it a vital component in the treatment of Tubercular Meningitis. * **Option D:** It is a **mandatory component** of short-course chemotherapy (SCC). Its inclusion allowed the duration of treatment to be reduced from 9–12 months to 6 months by rapidly eliminating the persistent intracellular pool of bacteria. **NEET-PG High-Yield Pearls:** * **Mechanism:** It is a prodrug converted to **pyrazinoic acid** by the enzyme **pyrazinamidase** (encoded by the *pncA* gene). * **Side Effects:** The most common side effect is **hyperuricemia** (due to inhibition of uric acid excretion), which can precipitate gout. It is also the **most hepatotoxic** of the first-line ATT drugs. * **Activity:** It is most active at an **acidic pH (5.5)**.
Explanation: **Explanation:** The management of HIV in pregnancy aims to achieve viral suppression to prevent Mother-to-Child Transmission (MTCT). Most conventional Antiretroviral Therapy (ART) drugs are considered safe, provided their benefits in preventing transmission outweigh potential risks [1]. **Why "All of the above" is correct:** * **Zidovudine (AZT):** Historically the "gold standard" for preventing vertical transmission [1]. It is a Nucleoside Reverse Transcriptase Inhibitor (NRTI) with extensive safety data. It is often administered intravenously during labor if the maternal viral load is high. * **Lamivudine (3TC):** Another NRTI frequently used in combination with other agents (like Tenofovir or Abacavir) [2]. It is well-tolerated and has a proven safety profile in pregnancy. * **Indinavir:** A Protease Inhibitor (PI). While newer PIs like Ritonavir-boosted Lopinavir or Darunavir are now more common, Indinavir is considered safe and non-teratogenic, though it requires monitoring for maternal side effects like nephrolithiasis. **Clinical Pearls for NEET-PG:** 1. **Drug of Choice:** Currently, the WHO and National guidelines recommend a TLE regimen (**Tenofovir + Lamivudine + Effavirenz**) or TLD (**Tenofovir + Lamivudine + Dolutegravir**) as first-line for pregnant women. 2. **Efavirenz Myth:** Previously thought to be teratogenic (neural tube defects), recent evidence confirms Efavirenz is **safe** to use throughout pregnancy. 3. **Nevirapine:** Safe, but requires caution if the CD4 count is >250 cells/mm³ due to the risk of hepatotoxicity. 4. **Avoid:** **Stavudine + Didanosine** combination should be avoided in pregnancy due to the high risk of fatal lactic acidosis. 5. **Neonatal Prophylaxis:** Infants born to HIV-positive mothers typically receive **Zidovudine or Nevirapine** syrup for 6–12 weeks post-delivery.
Explanation: The treatment of intestinal candidiasis requires antifungal agents that are either non-absorbable (acting locally within the gut lumen) or systemically absorbable drugs that reach the gastrointestinal mucosa. **Why Clotrimazole is the correct answer:** Clotrimazole is an imidazole derivative used exclusively for **topical** (skin, vaginal, or oropharyngeal) applications [1, 2]. It is not used for intestinal candidiasis because it is poorly absorbed from the GI tract and, more importantly, its oral administration is associated with significant gastrointestinal intolerance and potential toxicity. **Analysis of incorrect options:** * **Nystatin:** This is a polyene antifungal that is not absorbed from the GI tract [1]. It is the **drug of choice** for luminal intestinal candidiasis as it acts locally on the fungal cell membrane within the gut without causing systemic toxicity. * **Amphotericin B:** While primarily known for IV use, oral (non-absorbable) formulations of Amphotericin B exist specifically for treating intestinal candidiasis, acting similarly to Nystatin [1]. * **Ketoconazole:** This is a systemically absorbed azole. It can be used for various forms of candidiasis, including intestinal involvement, as it reaches the site via the bloodstream (though it has largely been replaced by Fluconazole due to side effects) [1]. **NEET-PG High-Yield Pearls:** 1. **Nystatin** is too toxic for systemic (IV) use; it is strictly used topically or orally for local GI action ("Swish and Swallow"). 2. **Clotrimazole** is often the first-line treatment for **Oral Thrush** (as troches) and **Vulvovaginal Candidiasis**, but never for intestinal or systemic infections [2]. 3. **Amphotericin B** remains the "gold standard" for most life-threatening systemic fungal infections despite its nephrotoxicity [1].
Explanation: **Explanation:** **Sulfamethoxazole + Trimethoprim (Co-trimoxazole)** is the drug of choice for both the **prophylaxis and treatment** of *Pneumocystis jirovecii* pneumonia (PCP) in HIV-positive patients. In immunocompromised individuals, particularly those with a CD4 count **<200 cells/mm³**, PCP is a major opportunistic infection. Co-trimoxazole works by inhibiting two consecutive steps in the bacterial/fungal folic acid synthesis pathway (synergistic sequential blockade), effectively preventing the replication of the organism. **Why other options are incorrect:** * **Azithromycin:** This is a macrolide used primarily for the prophylaxis of *Mycobacterium avium complex* (MAC) in HIV patients when CD4 counts drop below 50 cells/mm³. * **Acyclovir:** This is an antiviral agent used for infections caused by the Herpes Simplex Virus (HSV) and Varicella-Zoster Virus (VZV); it has no activity against fungi like *P. jirovecii*. * **Levofloxacin:** A fluoroquinolone used for bacterial respiratory infections and as a second-line agent for Tuberculosis, but it is ineffective against PCP. **High-Yield Clinical Pearls for NEET-PG:** * **Prophylaxis Threshold:** Start PCP prophylaxis in HIV patients if CD4 <200 cells/mm³ or if there is a history of oropharyngeal candidiasis. * **Alternative for PCP:** If a patient is allergic to sulfonamides, **Dapsone** or **Atovaquone** are the preferred alternatives. For severe cases, **Pentamidine** (IV) or **Primaquine + Clindamycin** can be used. * **Steroid Adjunct:** In active PCP treatment, if the $PaO_2 < 70$ mmHg or A-a gradient $> 35$ mmHg, corticosteroids are added to reduce inflammation caused by dying organisms.
Explanation: **Explanation:** Ethambutol is a key first-line antitubercular drug (ATT) that acts by inhibiting the enzyme **arabinosyl transferase**, thereby blocking mycobacterial cell wall synthesis. Its most significant and dose-dependent adverse effect is **Retrobulbar Neuritis**. **Why Green is the correct answer:** Ethambutol-induced optic neuritis typically manifests as a decrease in visual acuity, central scotomas, and specifically, **red-green color blindness**. Among these, **green color blindness (deuteranopia)** is often the earliest sign of toxicity. This occurs due to the drug’s chelating effect on copper, which interferes with mitochondrial function in the optic nerve fibers. **Analysis of Incorrect Options:** * **A. Red:** While red-green discrimination is lost as a pair, clinical testing (using Ishihara charts) often identifies the inability to distinguish green hues as the initial deficit. * **C. Blue & D. Yellow:** Blue-yellow color blindness (tritanopia) is not associated with Ethambutol. It is more commonly seen in conditions like autosomal dominant optic atrophy or as a side effect of drugs like Sildenafil (which causes a blue tint/cyanopsia). **Clinical Pearls for NEET-PG:** * **Monitoring:** Patients on Ethambutol must undergo baseline and monthly visual acuity and color vision testing. * **Reversibility:** The toxicity is generally reversible upon immediate discontinuation of the drug. * **Contraindication:** It is usually avoided in children (under 6 years) because they cannot reliably report changes in color vision or visual acuity. * **Renal Adjustment:** Ethambutol is primarily excreted by the kidneys; therefore, the dose must be adjusted in renal failure to prevent accumulation and toxicity.
Explanation: **Explanation:** The correct answer is **Streptomycin**. **Why Streptomycin is contraindicated:** Streptomycin is an **aminoglycoside** that is strictly contraindicated in pregnancy (Category D). It crosses the placental barrier and is known to be **ototoxic** to the developing fetus. Exposure during gestation can lead to permanent **congenital deafness** (damage to the 8th cranial nerve) and potential nephrotoxicity in the neonate. **Analysis of Incorrect Options:** * **Isoniazid (INH):** Considered safe in pregnancy. However, it is usually co-administered with **Pyridoxine (Vitamin B6)** to prevent peripheral neuropathy in both the mother and the fetus. * **Rifampicin:** Considered safe and is a core component of the RNTCP/WHO regimen for pregnant women. While it can theoretically cause neonatal hemorrhage (due to Vitamin K antagonism), this is rare and manageable. * **Ethambutol:** Generally considered the safest of the first-line anti-tubercular drugs during pregnancy, with no documented teratogenic effects. **NEET-PG High-Yield Pearls:** 1. **WHO/RNTCP Guidelines:** The standard treatment for TB in pregnancy is the same as in non-pregnant adults (**2HRZE + 4HRE**), simply excluding Streptomycin. 2. **Pyrazinamide:** While the WHO recommends its use, some older guidelines were cautious due to limited data; however, it is now widely accepted as safe in pregnancy. 3. **Second-line drugs:** Most second-line drugs (like Ethionamide and Fluoroquinolones) are avoided in pregnancy due to teratogenic risks. 4. **Breastfeeding:** All first-line anti-tubercular drugs are compatible with breastfeeding.
Explanation: **Sofosbuvir** is the correct answer as it is a cornerstone of modern **Hepatitis C Virus (HCV)** therapy [1, 2]. It is a **Direct-Acting Antiviral (DAA)** that functions as a potent inhibitor of the **NS5B RNA-dependent RNA polymerase**. By acting as a uridine nucleotide analog, it causes chain termination during viral RNA replication. It is highly effective across multiple HCV genotypes and is typically used in combination with other DAAs (like Ledipasvir or Velpatasvir).**Analysis of Incorrect Options:** * **Acyclovir:** A guanosine analog used primarily for **Herpes Simplex Virus (HSV)** and **Varicella-Zoster Virus (VZV)** [2]. It requires activation by viral thymidine kinase. * **Oseltamivir:** A neuraminidase inhibitor used for the treatment and prophylaxis of **Influenza A and B**. It prevents the release of new virions from infected host cells. * **Adefovir:** A nucleotide analog used for the treatment of **Chronic Hepatitis B (HBV)** [2]. It inhibits HBV DNA polymerase but is less commonly used today due to the preference for Tenofovir or Entecavir.**High-Yield Clinical Pearls for NEET-PG:** * **HCV Treatment Goal:** The goal is "**Sustained Virologic Response" (SVR)**, defined as undetectable HCV RNA 12–24 weeks after completing treatment [2]. * **NS5B Inhibitors:** Sofosbuvir (Nucleotide), Dasabuvir (Non-nucleotide). * **NS5A Inhibitors:** End in **"-asvir"** (e.g., Ledipasvir, Daclatasvir). * **NS3/4A Protease Inhibitors:** End in **"-previr"** (e.g., Simeprevir, Glecaprevir) [1]. *Mnemonic: P for Protease.* * Sofosbuvir is generally well-tolerated but should not be co-administered with **Amiodarone** due to the risk of severe symptomatic bradycardia.
Explanation: **Explanation:** **Correct Answer: B. Cytomegalovirus infection in AIDS patients** **Mechanism and Clinical Use:** Fomivirsen is a unique antiviral agent because it is the first **antisense oligonucleotide** approved for clinical use. It consists of a synthetic 21-nucleotide sequence that is complementary to the messenger RNA (mRNA) of the **Cytomegalovirus (CMV) immediate-early (IE2) gene**. By binding to this specific mRNA, it inhibits the translation of viral proteins, thereby halting viral replication. It is specifically indicated for the local treatment of **CMV retinitis** in patients with AIDS who are intolerant of, or have failed, other treatments (like Ganciclovir or Foscarnet). **Analysis of Incorrect Options:** * **Option A & C (HSV and VZV):** These infections are typically treated with DNA polymerase inhibitors such as **Acyclovir, Valacyclovir, or Famciclovir**. Fomivirsen does not target the genetic machinery of these viruses. * **Option D (Influenza):** Influenza is managed with neuraminidase inhibitors (e.g., **Oseltamivir**) or cap-dependent endonuclease inhibitors (e.g., **Baloxavir marboxil**). **High-Yield Clinical Pearls for NEET-PG:** * **Route of Administration:** Fomivirsen is administered via **intravitreal injection** because systemic levels are insufficient to treat ocular infections. * **Unique Class:** It is the "classic" example of an antisense drug in pharmacology textbooks. * **Current Status:** Although a landmark drug, it was voluntarily withdrawn from the market in many regions due to the high efficacy of Highly Active Antiretroviral Therapy (HAART), which reduced the incidence of CMV retinitis. * **Side Effects:** The most common side effect is **increased intraocular pressure** and intraocular inflammation (uveitis).
Explanation: ### Explanation The correct answer is **D. All of the above**. The treatment of Hepatitis C Virus (HCV) has evolved significantly, moving from non-specific antivirals to highly potent Direct-Acting Antivirals (DAAs). All three drugs listed target HCV replication through different mechanisms: 1. **Ribavirin:** A guanosine analogue that has been a cornerstone of HCV therapy for decades. It acts by inhibiting the enzyme **IMP dehydrogenase**, interfering with viral RNA synthesis, and inducing lethal mutations in the viral genome. While its use is declining in the era of DAAs, it is still used in difficult-to-treat cases (e.g., decompensated cirrhosis). 2. **Viramidine (Taribavirin):** This is a **prodrug of Ribavirin**. It is converted into ribavirin in the liver. Its primary clinical advantage is that it concentrates in hepatocytes and has lower uptake by red blood cells, significantly reducing the risk of **hemolytic anemia**, which is the major dose-limiting side effect of ribavirin. 3. **Merimepodib (VX-497):** This is a potent, selective, non-competitive **inhibitor of IMP dehydrogenase**. By depleting intracellular guanine nucleotide pools, it inhibits HCV RNA replication. It was primarily studied as an adjunct to interferon and ribavirin therapy. ### NEET-PG High-Yield Pearls: * **Ribavirin Side Effects:** The most characteristic side effect is **dose-dependent hemolytic anemia**. It is also highly **teratogenic** (contraindicated in pregnancy; effective contraception required for 6 months post-treatment). * **IMP Dehydrogenase Inhibitors:** Both Ribavirin and Merimepodib target this enzyme, which is the rate-limiting step in *de novo* guanosine nucleotide biosynthesis. * **Current Standard of Care:** Modern HCV treatment focuses on **DAAs** (e.g., Sofosbuvir, Ledipasvir, Velpatasvir), which target specific viral proteins like NS3/4A (protease), NS5A, and NS5B (polymerase).
Beta-Lactam Antibiotics
Practice Questions
Aminoglycosides
Practice Questions
Macrolides and Ketolides
Practice Questions
Tetracyclines
Practice Questions
Quinolones
Practice Questions
Sulfonamides and Trimethoprim
Practice Questions
Antimycobacterial Drugs
Practice Questions
Antifungal Agents
Practice Questions
Antiviral Drugs
Practice Questions
Antiparasitic Agents
Practice Questions
Principles of Antimicrobial Selection
Practice Questions
Antimicrobial Resistance
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free